Literature DB >> 35223357

An integrated chemo-informatics and in vitro experimental approach repurposes acarbose as a post-ischemic neuro-protectant.

Jyotirekha Das1, Fayaz Shaik Mahammad2, Rajanikant Golgodu Krishnamurthy1.   

Abstract

The increasing prevalence of ischemic stroke combined with limited therapeutic options highlights the compelling need for continued research into the development of future neuro-therapeutics. Death-Associated Protein Kinase 1 (DAPK1) and p53 protein-protein interaction serve as a signaling point for the convergence of apoptosis and necrosis in cerebral ischemia. In this study, we used an integrated chemo-informatics and in vitro experimental drug repurposing strategy to screen potential small-molecule inhibitors of DAPK1-p53 interaction from the United States of America Food and Drug Administration (FDA) approved drug database exhibiting post-ischemic neuroprotective and neuro-regenerative efficacy and mechanisms. The computational docking and molecular dynamics simulation of FDA-approved drugs followed by an in vitro experimental validation identified acarbose, an anti-diabetic medication and caloric restriction mimetic as a potential inhibitor of DAPK1-p53 interaction. The evaluation of post-ischemic neuroprotective and regenerative efficacy and mechanisms of action for acarbose was carried out using a set of experimental methods, including cell viability, proliferation and differentiation assays, fluorescence staining, and gene expression analysis. Post-ischemic administration of acarbose conferred significant neuroprotection against ischemia-reperfusion injury in vitro. The reduced fluorescence emission in cells stained with pS20 supported the potential of acarbose in inhibiting the DAPK1-p53 interaction. Acarbose prevented mitochondrial and lysosomal dysfunction, and favorably modulated gene expression related to cell survival, inflammation, and regeneration. BrdU staining and neurite outgrowth assay showed a significant increase in cell proliferation and differentiation in acarbose-treated group. This is the first study known to provide mechanistic insight into the post-ischemic neuroprotective and neuro-regenerative potential of acarbose. Our results provide a strong basis for preclinical studies to evaluate the safety and neuroprotective efficacy of acarbose against ischemic stroke. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13205-022-03130-5. © King Abdulaziz City for Science and Technology 2022.

Entities:  

Keywords:  Acarbose; Cerebral ischemia; Death-associated protein kinase; Drug repurposing; Neuro-regeneration; Oxygen glucose deprivation; Post-ischemic neuroprotection; p53

Year:  2022        PMID: 35223357      PMCID: PMC8847516          DOI: 10.1007/s13205-022-03130-5

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  64 in total

1.  Interplay between Notch and p53 promotes neuronal cell death in ischemic stroke.

Authors:  Priyanka Balaganapathy; Sang-Ha Baik; Karthik Mallilankaraman; Christopher G Sobey; Dong-Gyu Jo; Thiruma V Arumugam
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-15       Impact factor: 6.200

2.  miR-9 Upregulation Integrates Post-ischemic Neuronal Survival and Regeneration In Vitro.

Authors:  Sreekala S Nampoothiri; G K Rajanikant
Journal:  Cell Mol Neurobiol       Date:  2018-12-11       Impact factor: 5.046

3.  ACC1 (Acetyl Coenzyme A Carboxylase 1) Is a Potential Immune Modulatory Target of Cerebral Ischemic Stroke.

Authors:  Xin Wang; Yuxi Zhou; Dan Tang; Ziyu Zhu; Yan Li; Tingting Huang; Rolf Müller; Weifeng Yu; Peiying Li
Journal:  Stroke       Date:  2019-06-10       Impact factor: 7.914

Review 4.  Lysosomal membrane permeabilization and cell death.

Authors:  Fengjuan Wang; Raquel Gómez-Sintes; Patricia Boya
Journal:  Traffic       Date:  2018-09-12       Impact factor: 6.215

Review 5.  Caloric restriction: beneficial effects on brain aging and Alzheimer's disease.

Authors:  Caroline Van Cauwenberghe; Charysse Vandendriessche; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  Mamm Genome       Date:  2016-05-30       Impact factor: 2.957

Review 6.  Lysosomal membrane permeabilization as a key player in brain ischemic cell death: a "lysosomocentric" hypothesis for ischemic brain damage.

Authors:  Peter Lipton
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

7.  Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1α Stabilization.

Authors:  Charles K Davis; Sreekala S Nampoothiri; G K Rajanikant
Journal:  Mol Neurobiol       Date:  2018-03-14       Impact factor: 5.590

8.  Peroxiredoxin 2 battles poly(ADP-ribose) polymerase 1- and p53-dependent prodeath pathways after ischemic injury.

Authors:  Rehana K Leak; Lili Zhang; Yumin Luo; Peiying Li; Haiping Zhao; Xiangrong Liu; Feng Ling; Jianping Jia; Jun Chen; Xunming Ji
Journal:  Stroke       Date:  2013-02-21       Impact factor: 7.914

Review 9.  Glibenclamide in cerebral ischemia and stroke.

Authors:  J Marc Simard; Kevin N Sheth; W Taylor Kimberly; Barney J Stern; Gregory J del Zoppo; Sven Jacobson; Volodymyr Gerzanich
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

Review 10.  Liraglutide and its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events.

Authors:  Michał Wiciński; Maciej Socha; Bartosz Malinowski; Eryk Wódkiewicz; Maciej Walczak; Karol Górski; Maciej Słupski; Katarzyna Pawlak-Osińska
Journal:  Int J Mol Sci       Date:  2019-02-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.